Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center
Articles
TRK Fusion Inhibitors in Clinical Practice
Mark A. Socinski, MD, AdventHealth Cancer Institute;Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center;Lori J. Wirth, MD, Massachusetts General Hospital;Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine;Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center
April 28th 2021Experts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.
Read More
Key Considerations for Biomarker Testing
Mark A. Socinski, MD, AdventHealth Cancer Institute;Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center;Lori J. Wirth, MD, Massachusetts General Hospital;Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine;Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center
March 31st 2021Jyoti Patel, MD, FASCO, discusses the pros and cons of tissue versus blood for molecular testing of solid tumors.
Read More
Importance of Biomarker Testing for Solid Tumors
Mark A. Socinski, MD, AdventHealth Cancer Institute;Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center;Lori J. Wirth, MD, Massachusetts General Hospital;Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine;Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center
March 31st 2021Benjamin Levy, MD, and a multispecialty panel of experts discuss the importance of biomarker-directed therapy for appropriate solid tumors.
Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
